A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03597282 |
|
Recruitment Status :
Terminated
(Closed due to historically slow enrollment compounded by the COVID-19 pandemic.)
First Posted : July 24, 2018
Last Update Posted : September 3, 2020
|
Sponsor:
BioNTech US Inc.
Collaborator:
Apexigen America, Inc.
Information provided by (Responsible Party):
BioNTech SE ( BioNTech US Inc. )
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Terminated |
|---|---|
| Actual Primary Completion Date : | May 5, 2020 |
| Actual Study Completion Date : | August 11, 2020 |